미국의 안과 치료 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the u.S. eye care market size is expected to increase from USD 30.76 billion in 2025 to USD 33.14 billion in 2026 and reach USD 48.12 billion by 2031, growing at a CAGR of 7.75% over 2026-2031.

This report is Segmented by Product Category (Vision Correction, Ocular Health, Surgical & Implantable, Diagnostics), Mode of Purchase (Prescribed (Rx), OTC), Distribution Channel (Optical Retail Chains, Ophthalmology & Optometry Clinics, Ambulatory Surgery Centers, Hospitals, Retail Pharmacies, Online), Demographic (Children & Adolescents, Adults, Geriatric). The Market Forecasts are Provided in Terms of Value (USD).

U.S. Eye Care Market Trends and Insights

Aging-Linked Ocular Disease Burden Sustains Multi-Category Demand

The aging population continues to drive the United States eye care market. In 2024, 4.22 million adults were affected by glaucoma, with the older population exceeding 54 million. Conditions like cataracts, diabetic retinopathy, and age-related macular degeneration also rise with age, requiring ongoing treatment. Companies with diverse portfolios across multiple disease areas are better positioned to mitigate risks from reimbursement changes compared to single-category players.

Screen Time Expands the Dry-Eye and Vision Correction Addressable Market

Screen exposure has become a significant driver for the United States eye care market. Full-time employees averaged 97 hours of weekly screen time in 2025, with 68% reporting digital eye strain and 63% experiencing eye issues, up from 50% the previous year. This trend sustains demand for blue-light-filtering lenses, prescription eyewear, contact lenses, and dry-eye products, while expanding the market to include pediatric care through myopia management and related treatments.

Coverage Gaps and Cash-Pay Affordability Constrain Utilization

Coverage design remains a significant challenge for the United States eye care market. In 2024, 6.5 million Medicaid enrollees (12%) lived in states without routine adult eye exam coverage, while 14.6 million (27%) lacked coverage for glasses. Vision benefits are often treated as supplemental, making them narrower and prone to network gaps. This limits access for lower-income patients and older adults, delaying exams, eyewear purchases, and follow-ups, leaving a substantial portion of demand unmet.

Other drivers and restraints analyzed in the detailed report include:

1. Omnichannel Access and Managed Vision Care Deepen Market Penetration
2. Primary-Care AI Retinal Screening Expands the Diagnostic Funnel
3. Ophthalmology and Subspecialty Workforce Bottleneck Caps Service Throughput

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

In 2025, Vision Correction Products accounted for 51.44% of revenue, making it the largest product category in the United States eye care market. This reflects the widespread use of spectacles, contact lenses, and refractive corrections, supported by routine replacements, screen-related vision issues, and broad clinical and retail access. Ocular Health Products, the fastest-growing segment, is projected to expand at an 8.10% CAGR through 2031, driven by demand for dry-eye therapeutics, anti-VEGF treatments, and premium ocular supplements.

The market is shifting from episodic corrections to recurring disease management. Surgical and Implantable Products are gaining traction, with RxSight achieving 300,000 Light Adjustable Lens implants by April 2026 and Glaukos advancing Epioxa commercialization in Q1 2026. Diagnostics and Monitoring Systems are also growing as AI tools enhance screening access, favoring companies with strong regulatory capabilities and comprehensive portfolios.

Prescribed products represented 73.22% of purchases in 2025, highlighting the dominance of clinically directed categories in the United States eye care market. Prescription eyewear, specialty contact lenses, surgical implants, and retinal therapies rely on licensed practitioners, keeping the Rx channel central. Over-the-Counter products are forecast to grow at an 8.40% CAGR through 2031, driven by consumer spending on dry-eye drops, ocular vitamins, and allergy-related eye care, supported by aging demographics and preventive self-care trends.

The FTC Eyeglass Rule update in September 2024 improved prescription portability, enabling easier transitions across fulfillment channels. Tele-optometry platforms are further enhancing digital prescription workflows. While the Rx channel remains critical for high-value categories, digital prescription mobility supports both OTC and online Rx fulfillment, blurring the lines between prescribed and consumer-directed purchases.

List of Companies Covered in this Report:

1. AbbVie Inc. (Allergan Eye Care)
2. Alcon
3. Bausch + Lomb Corporation
4. Carl Zeiss
5. The Cooper Companies
6. EssilorLuxottica
7. Glaukos
8. Harrow, Inc.
9. HOYA
10. Johnson & Johnson Vision Care, Inc.
11. National Vision Holdings, Inc.
12. NIDEK Inc.
13. Regeneron Pharmaceuticals
14. RxSight, Inc.
15. Santen Pharmaceuticals
16. Sight Sciences, Inc.
17. STAAR Surgical
18. Topcon Healthcare, Inc.
19. VSP Vision
20. Warby Parker Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Aging-Linked Ocular Disease Burden
  • 4.2.2 Screen-Time-Driven Vision Correction and Dry-Eye Demand
  • 4.2.3 Omnichannel Access and Managed Vision Care Utilization
  • 4.2.4 Primary-Care AI Retinal Screening Expansion
  • 4.2.5 Durable Myopia-Management Outcomes Improve Clinician Confidence
• 4.3 Market Restraints
  • 4.3.1 Coverage Gaps and Cash-Pay Affordability Pressure
  • 4.3.2 Ophthalmology and Subspecialty Workforce Bottlenecks
  • 4.3.3 Tariff-Led Cost Inflation Across Frames, Lenses, and Equipment
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Bargaining Power of Suppliers
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Threat of New Entrants
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Product Category
  • 5.1.1 Vision Correction Products
  • 5.1.2 Ocular Health Products
  • 5.1.3 Surgical & Implantable Products
  • 5.1.4 Diagnostics & Monitoring Systems
  • 5.1.5 Others
• 5.2 By Mode of Purchase
  • 5.2.1 Prescribed (Rx) Products
  • 5.2.2 Over-the-Counter Products
• 5.3 By Distribution Channel
  • 5.3.1 Optical Retail Chains & Independent Optical Stores
  • 5.3.2 Ophthalmology Clinics & Optometry Stores
  • 5.3.3 Ambulatory Surgery Centers
  • 5.3.4 Hospitals
  • 5.3.5 Retail Pharmacies
  • 5.3.6 Online Channel
• 5.4 By Demographic
  • 5.4.1 Children & Adolescents
  • 5.4.2 Adults
  • 5.4.3 Geriatric

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 AbbVie Inc. (Allergan Eye Care)
  • 6.3.2 Alcon Inc.
  • 6.3.3 Bausch + Lomb Corporation
  • 6.3.4 Carl Zeiss Meditec AG
  • 6.3.5 CooperVision, Inc.
  • 6.3.6 EssilorLuxottica SA
  • 6.3.7 Glaukos Corporation
  • 6.3.8 Harrow, Inc.
  • 6.3.9 HOYA Corporation
  • 6.3.10 Johnson & Johnson Vision Care, Inc.
  • 6.3.11 National Vision Holdings, Inc.
  • 6.3.12 NIDEK Inc.
  • 6.3.13 Regeneron Pharmaceuticals, Inc.
  • 6.3.14 RxSight, Inc.
  • 6.3.15 Santen Pharmaceutical Co., Ltd.
  • 6.3.16 Sight Sciences, Inc.
  • 6.3.17 STAAR Surgical Company
  • 6.3.18 Topcon Healthcare, Inc.
  • 6.3.19 VSP Vision
  • 6.3.20 Warby Parker Inc.

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment